Sakar Healthcare Limited (SAKAR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sakar Healthcare Limited (SAKAR) has a cash flow conversion efficiency ratio of 0.101x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs305.87 Million ≈ $3.31 Million USD) by net assets (Rs3.03 Billion ≈ $32.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SAKAR cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Sakar Healthcare Limited - Cash Flow Conversion Efficiency Trend (2010–2026)
This chart illustrates how Sakar Healthcare Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sakar Healthcare Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sakar Healthcare Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Li-FT Power Ltd.
F:WS0
|
-0.002x |
|
AVerMedia Technologies Inc
TW:2417
|
0.036x |
|
Bien Yapi Urunleri Sanayi Turizm ve Ticaret A.S.
IS:BIENY
|
0.146x |
|
Golden Ventures Leasehold Real Estate Investment Trust
BK:GVREIT
|
0.026x |
|
Gansu Mogao Industrial Development Co Ltd
SHG:600543
|
-0.079x |
|
Kang Yong Electric Public Company Limited
BK:KYE
|
0.013x |
|
Olimpo Real Estate SA
MC:YORE
|
0.026x |
|
VS Industry Bhd
KLSE:6963
|
0.063x |
Annual Cash Flow Conversion Efficiency for Sakar Healthcare Limited (2010–2026)
The table below shows the annual cash flow conversion efficiency of Sakar Healthcare Limited from 2010 to 2026. For the full company profile with market capitalisation and key ratios, see market cap of Sakar Healthcare Limited.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs3.24 Billion ≈ $35.09 Million |
Rs393.71 Million ≈ $4.26 Million |
0.121x | +1.79% |
| 2025-03-31 | Rs2.85 Billion ≈ $30.87 Million |
Rs340.32 Million ≈ $3.68 Million |
0.119x | +27.82% |
| 2024-03-31 | Rs2.62 Billion ≈ $28.37 Million |
Rs244.67 Million ≈ $2.65 Million |
0.093x | -54.22% |
| 2023-03-31 | Rs1.73 Billion ≈ $18.75 Million |
Rs353.14 Million ≈ $3.82 Million |
0.204x | -27.26% |
| 2022-03-31 | Rs1.27 Billion ≈ $13.78 Million |
Rs356.99 Million ≈ $3.86 Million |
0.280x | +89.16% |
| 2021-03-31 | Rs984.52 Million ≈ $10.65 Million |
Rs145.77 Million ≈ $1.58 Million |
0.148x | +18.92% |
| 2020-03-31 | Rs813.20 Million ≈ $8.79 Million |
Rs101.25 Million ≈ $1.09 Million |
0.125x | -53.27% |
| 2019-03-31 | Rs717.04 Million ≈ $7.75 Million |
Rs191.03 Million ≈ $2.07 Million |
0.266x | +160.56% |
| 2018-03-31 | Rs514.93 Million ≈ $5.57 Million |
Rs52.65 Million ≈ $569.38K |
0.102x | +18606825.53% |
| 2017-03-31 | Rs355.03 Million ≈ $3.84 Million |
Rs195.09 ≈ $2.11 |
0.000x | -88.53% |
| 2016-03-31 | Rs191.82 Million ≈ $2.07 Million |
Rs918.64 ≈ $9.93 |
0.000x | -100.00% |
| 2015-03-31 | Rs148.28 Million ≈ $1.60 Million |
Rs41.76 Million ≈ $451.59K |
0.282x | -54.40% |
| 2014-03-31 | Rs138.71 Million ≈ $1.50 Million |
Rs85.67 Million ≈ $926.46K |
0.618x | +13.02% |
| 2013-03-31 | Rs121.19 Million ≈ $1.31 Million |
Rs66.23 Million ≈ $716.22K |
0.546x | +160.66% |
| 2012-03-31 | Rs137.59 Million ≈ $1.49 Million |
Rs28.84 Million ≈ $311.95K |
0.210x | +1.82% |
| 2011-03-31 | Rs132.75 Million ≈ $1.44 Million |
Rs27.33 Million ≈ $295.59K |
0.206x | +2334.89% |
| 2010-03-31 | Rs123.53 Million ≈ $1.34 Million |
Rs-1.14 Million ≈ $-12.31K |
-0.009x | -- |
About Sakar Healthcare Limited
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analge… Read more